Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

2 ETFs Fill The Prescription For High-Growth Biotech Stocks

By Investing.com (Tezcan Gecgil/Investing.com )ETFsNov 23, 2021 04:36AM ET
www.investing.com/analysis/2-etfs-fill-the-prescription-for-highgrowth-biotech-stocks-200609170
2 ETFs Fill The Prescription For High-Growth Biotech Stocks
By Investing.com (Tezcan Gecgil/Investing.com )   |  Nov 23, 2021 04:36AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

A number of health-care and biotech shares have recently been in the spotlight. In early October, Merck (NYSE:MRK)—covered in early November—gave a positive update on molnupiravir, a potential antiviral drug that it was developing with Ridgeback Therapeutics that has shown great results in the treatment of COVID-19. Then came similar news from Pfizer (NYSE:PFE) regarding Paxlovid, its antiviral drug candidate.

Meanwhile, Johnson & Johnson (NYSE:JNJ) announced it would spin off its consumer health division and concentrate mainly on pharmaceuticals as well as medical devices. And on Nov. 19, the CDC recommended COVID-19 vaccine boosters for all adults in the US. The announcement put BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), JNJ and Pfizer stocks on investors’ radar.

So, today we introduce two exchange-traded funds (ETFs) that focus on biotech names. To put this discussion in context, readers might be interested to know that the Dow Jones Biotechnology returned 19.1% in the past 12 months. Similarly, the Dow Jones US Pharmaceuticals Index is up close to 21%.

1. VanEck Biotech ETF

  • Current Price: $194.04
  • 52-Week Range: $157.17 – $222.22
  • Dividend Yield: 0.32%
  • Expense Ratio: 0.35% per year

Biotechnology is “the use of living organisms or their products to improve human health and the environment.” The global biotechnology market is expected to be valued at $2.44 trillion by 2028, implying a compound annual growth rate (CAGR) of more than 15.5% between 2021 and 2028.

The VanEck Biotech ETF (NASDAQ:BBH) invests in health-care companies that develop and market drugs based mainly on genetic analysis as well as diagnostic equipment. The fund started trading in December 2011.

BBH Weekly Chart.
BBH Weekly Chart.

BBH, which has 25 holdings, tracks the MVIS US Listed Biotech 25 Index. The top 10 names make up about 62% of net assets of $564.6 million, which makes the fund top heavy. Around 85% of the companies come from the US, followed by Ireland and Germany.

Leading holdings include Amgen (NASDAQ:AMGN), Moderna, IQVIA Holdings (NYSE:IQV), Gilead Sciences (NASDAQ:GILD), ICON (NASDAQ:ICLR) and Vertex Pharmaceuticals (NASDAQ:VRTX).

The fund returned 21.7% in the past year and 13.2% in 2021. Potential investors looking for a fund concentrating on some of the most important biotech names could consider investing around $190.

2. Global X Genomics & Biotechnology ETF

  • Current Price: $20.95
  • 52-Week Range: $19.34 – $28.45
  • Expense Ratio: 0.50% per year

This fund brings the genomics dimensions into the health-care investment thesis. Genomics is “the study of an organism's genome—its DNA—and how that information is applied.”

This niche market is forecast to grow from almost $28 billion in 2021 to close to $95 billion in 2028, implying a CAGR of almost 19.5%. Health professionals highlight the importance genomic sequencing has been playing in developing an effective global response against the coronavirus.

The Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) gives exposure to businesses that are likely to be at the forefront of advances in genomic science applications, including genomic sequencing, gene editing, genetic medicine as well as biotechnology. The fund was first listed in April 2019.

GNOM Weekly Chart.
GNOM Weekly Chart.

GNOM, which has 41 holdings, tracks the returns of the Solactive Genomics Index. The leading 10 stocks comprise about 42% of net assets of $264.3 million.

Among the top names on the roster are Biomarin Pharmaceutical (NASDAQ:BMRN), Genscript Biotech (HK:1548), Arrow Electronics (NYSE:ARW), Qiagen (NYSE:QGEN), Sarepta Therapeutics (NASDAQ:SRPT) and Pacific Biosciences (NASDAQ:PACB) of California.

GNOM is down about 9.5% in 2021 but returned 5.1% in the past 12 months. After hitting a record high of $28.45 in February, companies in the fund have come under pressure, and the ETF has lost more than 24% of its value. Buy-and-hold investors who can handle the short-term swings in the fund could consider buying around these levels.

2 ETFs Fill The Prescription For High-Growth Biotech Stocks
 

Related Articles

2 ETFs Fill The Prescription For High-Growth Biotech Stocks

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Joseph Obrzut
jzut Nov 23, 2021 6:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BBH mirrors IBB and BIB. GNOM looks as bad as XBI and LABU.
mohammad buksh
mohammad buksh Nov 23, 2021 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good luck
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email